Fundraising Fox
🦊/Companies
Sign in

Endo

Malvern, US · Founded 2023 · Delaware corporation · 1 known investors

Find your way into Endo

447 people in our graph share verified history with the Endo team — schools, employers, funds. One of them is your warm intro.

Brooke Balcomunlockedknows Blaise Coleman · together at Duke University - The Fuqua School of Business (overlapped)
×9knows the team · via Capgemini
×2knows the team · via AstraZeneca

Keenova is a specialty therapeutics company focused on rare, stigmatized, or unaddressed conditions across areas including immunology, urology, hepatology, ophthalmology, orthopedics, and critical care. Par Health develops generic pharmaceuticals, sterile injectables, and active pharmaceutical ingredients with U.S.-based manufacturing capabilities.

BiotechHealthtechMedical Devices

Founders & leadership

BCBlaise Coleman
Blaise ColemaninPresident; Chief Executive OfficerBlaise Coleman held executive leadership roles at Johnson & Johnson and AstraZeneca before serving as President and CEO of Endo, where he oversaw operational improvements and financial restructuring. He holds an MBA from Duke University's Fuqua School of Business and a BS from Widener University, with background in accounting and finance.
MMMatthew Maletta
Matthew MalettainExecutive Vice President; Chief Legal Officer; Secretary
FRFrank Raciti
Frank RacitiinVice President; Controller; Chief Accounting Officer
MBMark Bradley
Mark BradleyinExecutive Vice President; Chief Financial OfficerMark Bradley is Chief Financial Officer and Executive Vice President at Endo, a specialty therapeutics company developing treatments for rare and stigmatized conditions. He brings experience in global financial operations, capital markets transactions, corporate development, and financial restructuring.
SH
Scott HirschNamed on SEC filing
PE
Paul EfronNamed on SEC filing
PH
Paul HerendeenNamed on SEC filing
MY
Marc YoskowitzNamed on SEC filing
PB
Patrick BarryNamed on SEC filing
SL
Sophia LangloisNamed on SEC filing
AP
Andy PasternakNamed on SEC filing

Investors · 1

Signet Healthcare PartnersNew York · $10M – $50M

Reported raises · per SEC filings

Form D private placements

$170.6M disclosed across 1 round · 2024

▶$170.6MraisedMay 2024 · 404 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Scott HirschDirector
  • Paul EfronDirector
  • Paul HerendeenDirector
  • Marc YoskowitzDirector
  • Patrick BarryExecutive Officer
  • Blaise ColemanExecutive Officer, Director
  • Matthew MalettaExecutive Officer
  • Sophia LangloisDirector
  • Frank RacitiExecutive Officer
  • Mark BradleyExecutive Officer, Director
  • Andy PasternakDirector
Offering amount
$170.6M
Amount sold
$170.6M
First sale
Mar 2024
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Medscape48 shared keywordsMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.

Companies competing with Endo for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Endo Tools Therapeutics Secures $23 million in Series C Financing to Advance The endomina® technology and Commercialization of New endomina EZFuse Systemprnewswire.com · Jul 2026Endo Tools Therapeutics Raises €5M in Series C Funding - FinSMEsfinsmes.com · Feb 2019Endo-tech firm Sonendo raises $18 millionvcpost.com · Jun 2013

Frequently asked questions

What does Endo do?
Keenova is a specialty therapeutics company focused on rare, stigmatized, or unaddressed conditions across areas including immunology, urology, hepatology, ophthalmology, orthopedics, and critical care. Par Health develops generic pharmaceuticals, sterile injectables, and active pharmaceutical ingredients with U.S.-based manufacturing capabilities.
Who are Endo's investors?
Endo's investors include Signet Healthcare Partners.
How much funding has Endo raised?
Endo has disclosed $170.6M raised across 1 round.
Where is Endo headquartered?
Endo is headquartered in Malvern, US.